Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cellsâ€™ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-02	US$1.000	0.00%	168,581
26-07-01	US$1.000	-2.44%	146,746
26-06-30	US$1.025	+4.06%	221,107
26-06-29	US$0.9850	+1.55%	100,591
26-06-26	US$0.9700	+1.06%	141,263

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.000USD

Average target price

14.00USD

Spread / Average Target

+1,300.00%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-02 EDT			5-day change	1st Jan Change
1.000 ^USD	0.00%		+4.19%	-4.76%

06-24	Phio Pharmaceuticals Corp. Announces the Manufacture of the First Commercial-Scale Cgmp Batch of Ph-762 Drug Substance Has Commenced At Nitto Denko Avecia, Inc	CI
05-07	Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	11.62M 10.15M 9.32M 8.69M 16.48M 1.11B 16.76M 112M 43.5M 542M 43.62M 42.67M 1.87B	P/E 2026 *	-0.73x	P/E 2027 *	-1.16x
Enterprise Value	11.62M 10.15M 9.32M 8.69M 16.48M 1.11B 16.76M 112M 43.5M 542M 43.62M 42.67M 1.87B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	98.07%	Yield 2026 *	-	Yield 2027 *	-

06-24	Phio Pharmaceuticals Corp. Announces the Manufacture of the First Commercial-Scale Cgmp Batch of Ph-762 Drug Substance Has Commenced At Nitto Denko Avecia, Inc	CI
05-07	Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-08	Phio Pharmaceuticals Corp - Enters at the Market Offering Agreement with H.C. Wainwright on April 8, 2026	RE
03-30	Phio Pharmaceuticals Corp Announces Agreement With U.S. cGMP Manufacturing Source For Drug Product PH-762	CI
03-05	Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-23	Phio Pharmaceuticals Corp. Promotes Jennifer Phillips, Pharm.D., to Senior Vice President	CI
02-10	Phio Pharmaceuticals Corp. Announces Safety Monitoring Committee's Positive Wrap-Up on Lead Clinical Candidate PH-762 in Skin Cancer Trial	CI
01-20	Phio Pharmaceuticals Corp announces key tumor response data from PH-762 trial	RE
01-20	Phio Pharmaceuticals Announces Key Tumor Response Data from All Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial	CI
12-23	Phio Pharmaceuticals Corp to begin toxicology study for PH-762 before human trials - SEC filing	RE
12-23	Phio Pharmaceuticals Corp Announces Significant Step Forward in its Drug Development Program for PH-762	CI
12-18	Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
11-25	Phio Pharmaceuticals Corp. Announces Completion of Enrollment in Phase 1B Clinical Trial of Intasyl Sirna Lead Compound Ph-762	CI

25-10-31	Phio Pharmaceuticals Corp. Announces Resignation of Robert Ferrara as Lead Independent Director of the Board and Compensation Committee and the Audit Committee, Effective October 31, 2025	CI
24-02-06	HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating	MT
21-06-14	PHIO PHARMACEUTICALS : HC Wainwright Adjusts Phio Pharmaceuticals' Price Target to $6 From $4, Keeps Buy Rating	MT

Phio Pharmaceuticals Corp. Stock

Stocks

PHIO

US71880W5013

Biotechnology & Medical Research

Valuation: Phio Pharmaceuticals Corp.

Chart: Phio Pharmaceuticals Corp.

Latest news : Phio Pharmaceuticals Corp.

Analysts' recommendations: Phio Pharmaceuticals Corp.

Press Releases: Phio Pharmaceuticals Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Phio Pharmaceuticals Corp.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

06-26	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series	NE
06-25	Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026	NE
06-24	Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762	NE
06-18	Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026	NE
05-26	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series	NE

1 week	+4.19%
Current month	-2.44%
1 month	-10.71%
3 months	-21.88%
6 months	-8.26%
Current year	-4.76%

1 week	0.97	1.05
1 month	0.96	1.14
Current year	0.81	1.88
1 year	0.81	4.19
3 years	0.81	29.07
5 years	0.81	261.36
10 years	0.81	174,042.17

Manager	Title	Age	Since
Robert Bitterman CEO	Chief Executive Officer	75	-
Lisa Carson DFI	Director of Finance/CFO	-	2025-06-08
Melissa Maxwell CTO	Chief Tech/Sci/R&D Officer	-	2018-09-30

Director	Title	Age	Since
Robert Bitterman CHM	Chairman	75	2013-04-29
Curtis Lockshin BRD	Director/Board Member	65	2013-04-17
Jonathan Freeman BRD	Director/Board Member	58	2017-06-06

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-25	Robert Bitterman	Buy	Chief Executive Officer	10,000	0.0861%
02-04	Patricia Bradford	Free	Director	18,500	0.1719%
02-04	Curtis Lockshin	Free	Director	16,600	0.1542%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHIO PHARMACEUTICALS CORP.	0.00%	+4.19%	-59.68%	-96.13%	11.62M
ARGENX SE	+3.98%	+5.55%	+76.40%	+132.19%	58.73B
WUXI APPTEC CO., LTD.	-3.12%	+3.48%	+72.79%	+94.67%	53.92B
BIONTECH SE	+3.86%	+8.38%	-9.90%	-9.62%	24.67B
INSMED INCORPORATED	+4.30%	+6.82%	+13.60%	+428.91%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+2.62%	+11.26%	+42.48%	-3.52%	18.8B
GENMAB A/S	+4.11%	+8.89%	+44.60%	-27.36%	17.61B
PHARMAESSENTIA CORPORATION	+2.57%	+16.74%	+171.12%	+355.99%	16.25B
EXELIXIS, INC.	+3.50%	+4.92%	+26.07%	+192.26%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.15%	+16.51%	+39.38%	-	13.9B
Average	+2.59%	+8.38%	+41.69%	+118.60%	24.21B
Weighted average by Cap.	+2.20%	+7.21%	+56.89%	+135.58%

	2026 *	2027 *
Net sales	-	-
Net income	-18.21M -15.92M -14.61M -13.63M -25.84M -1.73B -26.27M -176M -68.2M -850M -68.39M -66.9M -2.93B	-23.13M -20.21M -18.56M -17.31M -32.81M -2.2B -33.36M -223M -86.59M -1.08B -86.84M -84.95M -3.72B
Net Debt	-	-